Marc Ribas-Aulinas
A5000249715- SARS-CoV-2 and COVID-19 Research
- Bacillus and Francisella bacterial research
- Animal Virus Infections Studies
- vaccines and immunoinformatics approaches
Institut Universitari d'Investigació en Atenció Primària Jordi Gol
2022-2023
In response to COVID-19 pandemic, we have launched a vaccine development program against SARS-CoV-2. Here report the safety, tolerability, and immunogenicity of recombinant protein RBD fusion heterodimeric SARS-CoV-2 (PHH-1V) evaluated in phase 1-2a dose-escalation, randomized clinical trial conducted Catalonia, Spain. 30 young healthy adults were enrolled received two intramuscular doses, 21 days apart PHH-1V formulations [10 µg (n = 5), 20 10), 40 10)] or control [BNT162b2 5)]. Each group...
Summary Background We report safety, tolerability, and immunogenicity of a recombinant protein RBD-fusion heterodimeric vaccine against SARS-CoV-2 (PHH-1V). Methods A dose-escalation, phase 1-2a, randomized clinical trial was performed in Catalonia, Spain. Each cohort had one safety sentinel that received PHH-1V the corresponding dose, remaining participants were randomly assigned to receive formulations [10µg (n=5), 20µg (n=10), 40µg (n=10)] or control BNT162b2 (n=5). Two intramuscular...